The effect of anagliptin on blood glucose and lipid levels in type 2 diabetes mellius

The effect of anagliptin on blood glucose and lipid levels in type 2 diabetes mellius - The hypoglycemic and lipidemic effect of anagliptin in type 2 diabetes mellius

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012533

Enrollment

100

Registered

2013-12-09

Start date

2013-12-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)before test registration -anagliptin within 2 weeks outpatient 2)Type 2 diabetes 3)HbA1c :more than 7.0%, less than 9% 4)No plan to add other OHA 5)Age more than 20, less than 85 6)Patients with written IC

Exclusion criteria

Exclusion criteria: 1)Allergy for vildagliptin, linagliptin, repaglinide and glimepiride severe infection, before operation, severe trauma 2)severe ketosis, diabetic coma within 6 months 3)severe hepatic dysfunction or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30) 4)pregnacy 5)Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
Change of HbA1c and lipid levels	—

Secondary

Measure	Time frame
1) Achiemement rate of blood glucose <130mg/dl 2) The change of glycemic and lipid parameters. 3)The analysis of backgorund factors which affect glycemic and lipid control	—

Countries

Japan

Contacts

Public ContactTadashi Yamakawa

Yokohama City University Medical Center Department of Endocrinology and Diabetes

naibunpi@urahp.yokohama-cu.ac.jp045-261-5656

Outcome results